BOSTON, June 29 (Reuters) - A 10th patient taking Biogen Idec Inc's Tysabri has developed a potentially deadly brain infection since the multiple sclerosis drug was reintroduced to the market in July ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results